Vifor Pharma and Angion Biomedica Corp announced results from the exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data, based on the signal demonstrated in the clinically-relevant MAKE90 secondary endpoint.
- Read more about Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/vifor-pharma-and-angion-report-topline-results-from-phase-ii-guard-trial-of-ang-3777-in-cardiac-surgery-associated-acute-kidney-injury
No comments:
Post a Comment